Abstract | BACKGROUND: MATERIALS AND METHODS: We retrospectively analyzed 1004 consecutive patients who were diagnosed with lung adenocarcinomas and tested for EGFR mutations between June 2011 and December 2014. RESULTS: EGFR mutations were detected in 49.2% of 1004 patients with lung adenocarcinomas. In multivariable analysis, EGFR mutations were significantly associated with early stage disease (stage I to II) at diagnosis (odds ratio [OR], 0.65; 95% confidence interval [CI], 0.49-0.87; P = 0.003). When adjusted for age, sex, smoking status, and screening, the adjusted proportion of EGFR mutations significantly decreased according to stage. The adjusted proportions of EGFR mutations were 57.6% (95% CI, 51.7%-63.3%) for stage I, 47.9% (95% CI, 36.9%-59.0%) for stage II, 47.5% (95% CI, 39.6%-55.5%) for stage III, and 43.4% (95% CI, 38.3%-48.6%) for stage IV (P = 0.0082). CONCLUSIONS: The presence of EGFR mutations is significantly associated with early stage disease at initial diagnosis in lung adenocarcinomas after adjusting for age, sex, smoking status, and screening. This finding implies that EGFR mutations may play a role as a positive prognostic marker.
|
Authors | Jaeyoung Cho, Sun Mi Choi, Jinwoo Lee, Chang-Hoon Lee, Sang-Min Lee, Jae-Joon Yim, Doo Hyun Chung, Chul-Gyu Yoo, Young Whan Kim, Sung Koo Han, Young Sik Park |
Journal | PloS one
(PLoS One)
Vol. 11
Issue 11
Pg. e0166821
( 2016)
ISSN: 1932-6203 [Electronic] United States |
PMID | 27861565
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Adenocarcinoma
(diagnosis, genetics)
- Adenocarcinoma of Lung
- Aged
- Biopsy
- DNA Mutational Analysis
- ErbB Receptors
(genetics)
- Female
- Humans
- Lung Neoplasms
(diagnosis, genetics)
- Male
- Middle Aged
- Mutation
- Mutation Rate
- Neoplasm Staging
- Odds Ratio
- Positron Emission Tomography Computed Tomography
- Retrospective Studies
|